Clinical Milestones. Celgene shall make the following clinical milestone payments to Jounce that are set forth below upon the first achievement by or on behalf of Celgene, its Affiliates or Sublicensees of the Clinical Milestone Events set forth below with respect to the first Co-Co Product that achieves such event. For clarity, each milestone set forth below shall be due and payable one time only (regardless of the number of Co-Co Products to achieve any such Clinical Milestone Event). Clinical Milestone Event (For the first Co-Co Product that achieves such event) Milestone Payments (in $ millions) [***] [***] [***] [***] [***] [***]
Clinical Milestones. Event The First Profile to Achieve the Event The Second Profile to Achieve the Event Start of Phase I Study (first patient, first dosing) $[**] regardless of indication $[**] regardless of indication Start of Phase II Study (first patient, first dosing) $[**] for the first Major Indication $[**] for the first Major Indication Start of Phase II Study (first patient, first dosing) $[**] for the first Minor Indication $[**] for the first Minor Indication Start of Phase III Study (first patient, first dosing) $[**] for the first Major Indication $[**] for the first Major Indication Start of Phase III Study (first patient, first dosing) $[**] for the first Minor Indication $[**] for the first Minor Indication The Phase I Study milestone set forth in this Section 7.4.2 shall be payable only once for each Profile. All other milestones set forth in this Section 7.4.2 at each milestone event shall be payable only once for each Profile and only once for each Major Indication and Minor Indication, irrespective of Profile. For the avoidance of doubt: (a) in the event that a Phase II Study is commenced in [**] (a Major Indication) in two Profiles, only one (1) milestone shall be due; (b) in the event that a Phase II Study is commenced in [**] and in [**] (both of which are Major Indications) in the same Profile, only one (1) milestone shall be due; (c) in the event that a Phase II Study is commenced in [**] in the Bcl-2 Selective Profile and a Phase II Study is commenced in [**] in the Dual Profile, a Major Indication milestone for each shall be due; (d) in the event that a Phase II Study is commenced in [**] in the Bcl-2 Selective Profile (at which point the first Major Indication milestone is paid) and then a Phase II Study is commenced in [**] in the Bcl-2 Selective Profile (at which point no Major Indication milestone is paid) and subsequently to these two trials, a Phase II Study is commenced in [**] in the Dual Profile, then a second Major Indication milestone shall be due; and (e) in the event that the first Profile to be Developed by Novartis achieves the Phase I Study milestone and achieves the Phase II Study and Phase III Study Milestones for both a Major Indication and a Minor Indication, a total of $[**] shall be payable hereunder. If an NDA is filed after the end of a Phase II Study for a Licensed Compound, then the Phase III Study milestone event shall be deemed achieved as of the date of such filing.
Clinical Milestones. In consideration for the rights granted to Roche under this Agreement, Roche shall make the following one-time, non-refundable, non-creditable milestone payments to Prothena (up to a total of $[*] per Licensed Product) within [*] after the achievement of the relevant milestone for each Licensed Product and receipt by Roche of an invoice for such amount from Prothena; [*]: Milestone Event Payment (i) [*] $15,000,000 (ii) [*] $[*] (iii) [*] $[*] (iv) [*] $[*] Notwithstanding the foregoing, [*]. The following summarizes the percentage of the payments set forth above that are due with respect to various types of Licensed Compounds: Type of Licensed Compound Percentage of milestone amount due to Prothena (based on the table immediately above), if such Licensed Compound [*] Percentage of milestone amount due to Prothena (based on the table immediately above), if such Licensed Compound [*] [*] [*]% [*]% [*] [*]% [*]% [*] [*]% [*]% [*] [*]% [*]% The Parties will coordinate to have separate invoices with respect to each milestone payment so that accounting can be allocated appropriately (based on [*] or as otherwise mutually agreed by the JFT) to Roche Nutley and Prothena US for the portion of such milestone payment related to the United States and to Roche Basel and Prothena Ireland for the balance of such milestone payment.
Clinical Milestones. Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
Clinical Milestones a. With respect to a first Product, Amgen shall pay to GENE the following one-time, non-refundable, non-creditable payments via wire transfer to an account designated by GENE within ***** days following the achievement by Amgen, its Affiliates or sublicensees, of each of the clinical milestones set forth below: Milestone Event Milestone Payment
Clinical Milestones. With respect to each Product (irrespective of the Field of Use in which such event occurs), Novartis shall pay to Celgene the nonrefundable milestone payments set forth below in accordance with Section 8.1(a): ----------------------------------------------------------------------- MILESTONE EVENT MILESTONE PAYMENT ----------------------------------------------------------------------- Submission of IND for Product $3.0 million ----------------------------------------------------------------------- Commencement of Phase II Clinical Trials of Product $2.0 million ----------------------------------------------------------------------- Commencement of Phase III Clinical Trials of Product $4.0 million ----------------------------------------------------------------------- Submission of an NDA for Product $6.0 million ----------------------------------------------------------------------- Regulatory Approval of Product in the United States $8.0 million ----------------------------------------------------------------------- Regulatory Approval of Product in a Major Market $4.0 million other than the United States or Japan ----------------------------------------------------------------------- Regulatory Approval of Product in Japan $2.0 million ----------------------------------------------------------------------- provided, however, that if (i) a Product is abandoned during development after one or more of the milestone payments under this Section 7.2(b) has been made and (ii) a Product comprising or containing a Back-Up Compound is developed for the same indication as the abandoned Product to replace such abandoned Product, then only those milestone payments under this Section 7.2(b) that were not previously made with respect to such abandoned Product shall be payable with respect to the Product comprising or containing such Back-Up Compound. Payments made to Celgene pursuant to this Section 7.2 are non-refundable and may not be credited against any other payments payable by Novartis to Celgene under this Agreement.
Clinical Milestones. Hyseq will pay to Aurora the following non-creditable, non-refundable milestone payments for the first, and only the first, Hyseq Product within [***] following achievement of each of the following milestone events: Milestone Payment --------- ------- [***]
Clinical Milestones. First site initiation of protocol for Sarcoma Cohort 2 of the Phase I/IIa Sarcoma cancer study (“Sarcoma Cohort 2”) 2.5 First site initiation of protocol for Sarcoma Cohort 3 of the Phase I/IIa Sarcoma study (“Sarcoma Cohort 3”) 2.5 First site initiation of protocol for the Phase I/IIa NSCLC study included in the Initial Development Plan (“NSCLC Study”) 2.5 *** 2.5 *** *** *** *** *** *** *** *** Initiation of companion diagnostic development program as defined in the Initial Development Plan 2.0 *** *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
Clinical Milestones. On an Amgen Gene Target-by-Amgen Gene Target basis, within thirty (30) days following the first occurrence or achievement by the performance of Amgen, its Affiliate or Sublicensee of each of the clinical milestones set forth below with respect to the first Product to each Amgen Gene Target, Amgen shall pay to Isis the one-time, non-refundable, non-creditable milestone payment set forth below: MILESTONE EVENT MILESTONE PAYMENT ------------------------------------------------- --------------------------- [***] ---------------------
Clinical Milestones. In consideration of the grant of license rights to ALTANA hereunder, ALTANA shall make the payments set forth below for each Product per Accepted or Viable Y3H Target to achieve the corresponding clinical milestone event with respect to Products as set forth below. ALTANA shall promptly notify GPC of the occurrence of any milestone event. Notwithstanding the foregoing, in a case where a Product directed against an Accepted or Viable Y3H Target fails in clinical development, and ALTANA moves another Product against the same Accepted or Viable Y3H Target into clinical development (a “Substituted Product”) as a backup to the failed Product, then clinical milestone payments previously paid in connection with the failed Product shall not be due on a Substituted Product. Fifty percent (50%) of payments made pursuant to this Section with respect to each subsequent Product directed against the same Accepted or Viable Y3H Target after the first such Product (and where such subsequent Product is not a Substituted Product) shall be credited against payments due to GPC pursuant to Section 6.2.
